NRT6008
Lymph Node Metastases
Chengdu New Radiomedicine Technology Co. LTD.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
15 Active assets in the Lymph Node Metastases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Inno-206 Laura M. Spring, MD | Phase 3 | BB |
Cyclophosphamide Laura M. Spring, MD | Phase 3 | BB |
Indocyanine Green Isabelle Henskens | Phase 4 | BB |
TAMOXIFEN National Cancer Institute (NCI) | Phase 3 | BB |
Inno-206 National Cancer Institute (NCI) | Phase 3 | BB |
View all 24 →
Same molecule, other indications
NRT6008 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →